Literature DB >> 23483715

Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Charles Pierrot-Deseilligny1, Jean-Claude Souberbielle.   

Abstract

The contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis (MS) is reviewed. Among the multiple recently discovered actions of vitamin D, an immunomodulatory role has been documented in experimental autoimmune encephalomyelitis and in humans. This action in the peripheral immune system is currently the main known mechanism through which vitamin D might influence MS, but other types of actions could be involved within the central nervous system. Furthermore, vitamin D insufficiency is widespread in temperate countries and in patients with MS at the earliest stages of the disease, suggesting that the deleterious effects related to vitamin D insufficiency may be exerted in these patients. In fact, many genetic and environmental risk factors appear to interact and contribute to MS. In genetics, several human leukocyte antigen (HLA) alleles (more particularly HLA-DRB1*1501) could favour the disease whereas some others could be protective. Some of the genes involved in vitamin D metabolism (e.g. CYP27B1) also play a significant role. Furthermore, three environmental risk factors have been identified: past Epstein-Barr virus infection, vitamin D insufficiency and cigarette smoking. Interactions between genetic and environmental risk or protective factors may occur during the mother's pregnancy and could continue during childhood and adolescence and until the disease is triggered in adulthood, therefore possibly modulating the MS risk throughout the first decades of life. Furthermore, some clinical findings already strongly suggest that vitamin D status influences the relapse rate and radiological lesions in patients with MS, although the results of adequately powered randomized clinical trials using vitamin D supplementation have not yet been reported. While awaiting these incontrovertible results, which might be long in coming, patients with MS who are currently in vitamin D insufficiency should be supplemented, at least for their general health status, using moderate doses of the vitamin.

Entities:  

Keywords:  Epstein–Barr virus; genetics; multiple sclerosis; smoking; vitamin D

Year:  2013        PMID: 23483715      PMCID: PMC3582312          DOI: 10.1177/1756285612473513

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  363 in total

1.  Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults.

Authors:  Heike A Bischoff-Ferrari; Thomas Dietrich; E John Orav; Bess Dawson-Hughes
Journal:  Am J Med       Date:  2004-05-01       Impact factor: 4.965

2.  Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle.

Authors:  M T Kampman; T Wilsgaard; S I Mellgren
Journal:  J Neurol       Date:  2007-03-21       Impact factor: 4.849

3.  DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27.

Authors:  Hekla Sigmundsdottir; Junliang Pan; Gudrun F Debes; Carsten Alt; Aida Habtezion; Dulce Soler; Eugene C Butcher
Journal:  Nat Immunol       Date:  2007-01-28       Impact factor: 25.606

4.  Time of birth, residential solar radiation and age at onset of multiple sclerosis.

Authors:  Tzu-Yun McDowell; Sania Amr; Patricia Langenberg; Walter Royal; Christopher Bever; William J Culpepper; Douglas D Bradham
Journal:  Neuroepidemiology       Date:  2010-03-18       Impact factor: 3.282

5.  Urinary calcium response to high dose vitamin D3 with calcium supplementation in patients with multiple sclerosis.

Authors:  Samantha M Kimball; Jodie M Burton; Paul G O'Connor; Reinhold Vieth
Journal:  Clin Biochem       Date:  2011-05-05       Impact factor: 3.281

6.  Multiple sclerosis after infectious mononucleosis.

Authors:  Trine Rasmussen Nielsen; Klaus Rostgaard; Nete Munk Nielsen; Nils Koch-Henriksen; Sven Haahr; Per Soelberg Sørensen; Henrik Hjalgrim
Journal:  Arch Neurol       Date:  2007-01

Review 7.  Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).

Authors:  Amy M Burrell; Adam E Handel; Sreeram V Ramagopalan; George C Ebers; Julia M Morahan
Journal:  Discov Med       Date:  2011-03       Impact factor: 2.970

Review 8.  The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications.

Authors:  C P Earthman; L M Beckman; K Masodkar; S D Sibley
Journal:  Int J Obes (Lond)       Date:  2011-06-21       Impact factor: 5.095

9.  Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis.

Authors:  Judith Staples; Anne-Louise Ponsonby; Lynette Lim
Journal:  BMJ       Date:  2010-04-29

10.  Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis.

Authors:  Linn Hofsøy Steffensen; Svein Ivar Mellgren; Margitta T Kampman
Journal:  J Neurol       Date:  2009-10-01       Impact factor: 4.849

View more
  21 in total

1.  Lower 25-Hydroxyvitamin D Is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis.

Authors:  C Wang; Z Zeng; B Wang; S Guo
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

2.  Evaluation of Delta-Aminolevulinic Dehydratase Activity, Oxidative Stress Biomarkers, and Vitamin D Levels in Patients with Multiple Sclerosis.

Authors:  Carla Roberta Nunes Polachini; Roselia Maria Spanevello; Daniela Zanini; Jucimara Baldissarelli; Luciane Belmonte Pereira; Maria Rosa Chitolina Schetinger; Ivana Beatrice Mânica da Cruz; Charles Elias Assmann; Margarete Dulce Bagatini; Vera Maria Morsch
Journal:  Neurotox Res       Date:  2015-12-21       Impact factor: 3.911

Review 3.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner.

Authors:  Celia Oreja-Guevara; Heinz Wiendl; Bernd C Kieseier; Laura Airas
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

4.  miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.

Authors:  Naeim Ehtesham; Fariborz Khorvash; Majid Kheirollahi
Journal:  J Mol Neurosci       Date:  2016-10-17       Impact factor: 3.444

Review 5.  Association between vitamin D receptor polymorphisms and multiple sclerosis: systematic review and meta-analysis of case-control studies.

Authors:  Kalthoum Tizaoui; Wajih Kaabachi; Agnès Hamzaoui; Kamel Hamzaoui
Journal:  Cell Mol Immunol       Date:  2014-07-07       Impact factor: 11.530

6.  miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.

Authors:  Maryam Ahmadian-Elmi; Ali Bidmeshki Pour; Reza Naghavian; Kamran Ghaedi; Somayeh Tanhaei; Tayebeh Izadi; Mohammad Hossein Nasr-Esfahani
Journal:  Immunogenetics       Date:  2015-11-13       Impact factor: 2.846

7.  Vitamin D-binding protein controls T cell responses to vitamin D.

Authors:  Martin Kongsbak; Marina Rode von Essen; Trine Bøegh Levring; Peter Schjerling; Anders Woetmann; Niels Ødum; Charlotte Menné Bonefeld; Carsten Geisler
Journal:  BMC Immunol       Date:  2014-09-18       Impact factor: 3.615

Review 8.  Vitamin D and Neurological Diseases: An Endocrine View.

Authors:  Carolina Di Somma; Elisabetta Scarano; Luigi Barrea; Volha V Zhukouskaya; Silvia Savastano; Chiara Mele; Massimo Scacchi; Gianluca Aimaretti; Annamaria Colao; Paolo Marzullo
Journal:  Int J Mol Sci       Date:  2017-11-21       Impact factor: 5.923

9.  Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis.

Authors:  George A Jelinek; Claudia H Marck; Tracey J Weiland; Naresh Pereira; Dania M van der Meer; Emily J Hadgkiss
Journal:  BMC Neurol       Date:  2015-08-05       Impact factor: 2.474

10.  A Double-Blind, Placebo Controlled, Randomized Trial to Assess the Impact of a Monthly Administration of 50,000 IU of Vitamin D3 for 6 Months on Serum Levels of 25-Hydroxyvitamin D in Healthy Young Adults.

Authors:  E Brunel; M Schnitzler; M Foidart-Dessalle; J C Souberbielle; E Cavalier
Journal:  Int J Endocrinol       Date:  2013-11-13       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.